eFFECTOR’s lead lung cancer program falls through, stock crashes

eF­FEC­TOR Ther­a­peu­tics won’t be mov­ing its lead can­di­date for­ward in front­line non-small cell lung can­cer af­ter its ex­per­i­men­tal drug failed a Phase 2 study.

In the KICK­START tri­al, pa­tients with PD-L1 ≥50% re­ceived Mer­ck’s Keytru­da with ei­ther tomivosert­ib or place­bo as front­line treat­ment. Me­di­an pro­gres­sion-free sur­vival in the tomivosert­ib arm was 13 weeks com­pared to 11.7 weeks with place­bo, and the dif­fer­ence was not sta­tis­ti­cal­ly sig­nif­i­cant, eF­FEC­TOR re­port­ed on Thurs­day. Over­all sur­vival da­ta were im­ma­ture, but there was no trend fa­vor­ing the ex­per­i­men­tal arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.